E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bind to acetylcholine receptors at the postsynaptic neuromuscular junction, inhibiting the excitatory effects of the neurotransmitter acetylcholine. |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028417 |
E.1.2 | Term | Myasthenia gravis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety and tolerability of CFZ533 as an add-on therapy to standard of care in moderate to severe MG patients.
• To evaluate the efficacy of IV CFZ533 as an add-on therapy to standard of care in patients with moderate to severe MG after 24 weeks of treatment. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of CFZ533 throughout the 24 weeks treatment period
and the decay in efficacy throughout the 24 weeks follow-up period.
• To evaluate changes in patient’s quality of life (QOL) throughout 24 weeks
the treatment period.
• To evaluate the pharmacokinetics of CFZ533
• To evaluate the pharmacodynamics of CFZ533
• To assess immunogenicity of CFZ533 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosis of MG class IIa to IVa inclusive (Myasthenia Gravis
Foundation of America Clinical Classification).
• Quantitative Myasthenia Gravis (QMG) score of 10 or greater. If the
QMG score is < 15,
no more than 4 points may be derived from items 1 or 2 (ocular motility
disturbance and ptosis).
• Documented history of acetylcholine receptor (AChR) or Muscle
Specific Kinase (MuSK) antibody positive (assessed at screening if no
medical history available).
• Only one immunosuppressant or immunomodulatory drug at a stable
dose is allowed during the study (i) azathioprine and mycophenolate
mofetil must be stable for at least 4 months prior to randomization (ii)
cyclosporine must be
stable for at least 3 months prior to randomization.
If the patient is on oral corticosteroids, methotrexate or tacrolimus at
screening, the dose must be stable for at least 1 month prior to
randomization.
• If the patient is on cholinesterase inhibitors at screening, the dose
must be stable for at least 2 weeks prior to randomization.
• Women of child-bearing potential, defined as all women physiologically
capable of becoming pregnant, may be included in the study if they are
using highly effective methods of contraception during the study and for
12 weeks after study treatment. |
|
E.4 | Principal exclusion criteria |
• MGFA grade I, IVb, or V disease.
• Documented presence of unresected thymoma.
• Patients having undergone thymectomy or thymo thymectomy
(resection of thymoma) within 6 months of screening.
• Patients having received any of the following treatments prior to
randomization:
IVIg or plasma exchange within 8 weeks oral or IV cyclosphosphamide
treatment within 3 months; IV corticosteroid bolus (dose higher than 1
mg/kg) within 3 months; belimumab within 6 months. For patients who
received belimumab earlier, B cell count should be within normal range;
rituximab within 12 months. For patients who received rituximab earlier,
B cell count should be within normal range; any other biologic or an
investigational drug within 1 month or five times the half-life, whichever
is longer.
• Live vaccines within 4 weeks prior to randomization.
• Patients who are at significant risk for TE as judged by the investigator
or have any one of the following:
- History of either thrombosis or 3 or more spontaneous abortions with
or
- without the presence of anti-cardiolipin autoantibodies;
• Presence of prolonged partial thromboplastin time (PTT). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Mean change from baseline in the QMG Score for Disease Severity after 24 weeks of treatment (primary endpoint).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
After 24 weeks of treatment |
|
E.5.2 | Secondary end point(s) |
• Mean Change from baseline in QMG Score and MGC Score..
• Proportion of patients with improvement by ≥ 3 points in QMG score.
• Proportion of patients with worsening by ≥ 3 points in QMG score.
• Proportion of patients intolerant to steroid taper.
• Proportion of patients who discontinued due to inefficacy or worsening.
• Mean change from baseline in the MG-ADL and MG QOL-15.
• Free CFZ533 in plasma
• Free CD40 on B cells, total CD40 on B cells and total soluble CD40 in plasma
• Quantitative analysis of anti-CFZ533 antibodies in plasma |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 7 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Denmark |
Germany |
Russian Federation |
Taiwan |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 2 |